PSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.

Psychiatry and Clinical Psychopharmacology, an open-access journal published by AVES since 2017, is dedicated to advancing the fields of psychiatric medicine and psychopharmacology. With an ISSN of 2475-0573 and an E-ISSN of 2475-0581, this journal aims to provide a platform for disseminating innovative research and clinical findings relevant to mental health professionals and researchers. Although it currently holds a Q3 ranking in Pharmacology (medical) and a Q4 ranking in Psychiatry and Mental Health according to the 2023 category quartiles, the journal has established itself as a significant contributor to evolving discussions in these critical fields. Based in the United Kingdom, the journal encompasses diverse topics, ranging from pharmacological treatments to novel therapeutic approaches in psychiatry, thereby appealing to a broad audience of clinicians, scientists, and students. The open-access model ensures that all research is readily available, fostering an environment of collaboration and knowledge-sharing as the journal converges until 2024 to encompass the latest advancements in both pharmacology and clinical psychopharmacology.

Therapeutic Advances in Psychopharmacology is a leading open-access journal published by SAGE Publications Ltd, focusing on the dynamic integration of pharmacological therapies and psychological health. Since its inception in 2011, this journal has made a significant impact on the fields of pharmacology and psychiatry, consistently earning a Q1 ranking in both categories as of 2023, reflecting its esteemed position within the scientific community. With an impressive Scopus rank placing it in the top 15% across relevant disciplines, the journal serves as a vital platform for researchers, professionals, and students eager to explore cutting-edge advancements in psychopharmacology. The open-access model, established in 2019, ensures that groundbreaking research is accessible to a wide audience, fostering collaboration and innovation in therapeutic strategies for mental health disorders. Through the dissemination of high-quality research and reviews, Therapeutic Advances in Psychopharmacology is committed to advancing understanding and practice within this critical field.

JOURNAL OF PSYCHOPHARMACOLOGY, published by SAGE Publications Ltd, is a leading peer-reviewed journal that explores the intricate dynamics of pharmacological interventions in mental health and psychiatry. With an ISSN of 0269-8811 and an E-ISSN of 1461-7285, this esteemed journal has established its reputation in the field since its inception in 1987, converging research excellence into 2024. Recognized as a Q1 journal in various categories including Medicine (miscellaneous), Pharmacology, and Psychiatry and Mental Health, it ranks impressively within the top percentile in Scopus, standing at #64 out of 567 in Psychiatry and Mental Health, and #31 out of 272 in Medical Pharmacology. The journal serves as a vital resource for researchers, professionals, and students, providing insightful articles that advance the understanding of psychopharmacological effects and innovations. Although it does not offer open access, the journal's extensive research and impactful findings make it essential reading for anyone engaged in the field. For those seeking to stay at the forefront of psychopharmacology, the JOURNAL OF PSYCHOPHARMACOLOGY is an invaluable asset.

Klinik Psikiyatri Dergisi - Turkish Journal of Clinical Psychiatry is a distinguished open-access journal dedicated to the evolving field of psychiatry and mental health. Published by KLINIK PSIKIYATRI DERGISI in Turkey since 1998, this journal aims to provide a platform for the dissemination of research, clinical studies, and reviews that contribute to the understanding of psychological disorders and treatment methodologies. With an ISSN of 1302-0099 and an E-ISSN of 2146-7153, the journal is indexed in various databases, although it currently holds a rank of 460/567 in the Scopus ranking for the category of Medicine: Psychiatry and Mental Health. The journal operates under an open-access model, ensuring that research findings are readily accessible to a wide audience, contributing to greater knowledge and awareness in the field. As it converges from 2017 to 2024, Klinik Psikiyatri Dergisi continues to strive for excellence, providing valuable insights and resources for researchers, professionals, and students interested in the complexities of mental health.

The American Journal of Psychiatry, published by the renowned American Psychiatric Publishing, Inc., stands as a premier platform in the field of Psychiatry and Mental Health. With its inaugural edition released in 1945, this esteemed journal has consistently provided a wealth of knowledge, shaping the landscape of psychiatric research and practice globally. Notably, in the latest 2023 Scopus rankings, it achieved an impressive rank of #7 out of 567 journals in its category, placing it in the top 2% percentile, indicative of its substantial impact within the field. The journal is committed to publishing high-quality, peer-reviewed original research, clinical studies, and reviews that advance psychiatric knowledge and treatment options. Although it does not currently offer open access, its contributions are vital for researchers, clinicians, and students dedicated to improving mental health care and understanding complex mental health disorders. As an essential resource, it continues to foster scholarly communication among professionals who are at the forefront of psychiatric science.

ACTA PSYCHIATRICA SCANDINAVICA is a leading journal in the field of Psychiatry and Mental Health, published by Wiley since its inception in 1926. With a strong commitment to advancing psychiatric research, this esteemed journal boasts an impressive impact factor and ranks within the top 7% of its category, reflecting its influence and relevance in the field. Operating without an Open Access model, the journal serves as a vital resource for professionals, researchers, and students keen on accessing high-quality, peer-reviewed studies focused on mental health issues. The scope of ACTA PSYCHIATRICA SCANDINAVICA spans a broad spectrum of psychiatric topics, providing a platform for groundbreaking research and clinical practice insights. Based in the United Kingdom and featuring contributions from experts worldwide, the journal continues to shape the future of psychiatric research through its rigorous publication standards and commitment to scholarly excellence.

Asia-Pacific Psychiatry is a leading academic journal published by WILEY, focused on the diverse and rapidly evolving fields of psychiatry and mental health within the Asia-Pacific region. With an ISSN of 1758-5864 and an E-ISSN of 1758-5872, this journal has been recognized for its significant impact, holding a Q1 ranking in Medicine (miscellaneous) and a Q2 ranking in Psychiatry and Mental Health as of 2023. Its commendable Scopus ranking places it at Rank #83 out of 567 in its category, highlighting its influence and relevance in contemporary research. The journal aims to facilitate the dissemination of high-quality research, reviews, and clinical insights that address mental health challenges, promote global understanding, and encourage collaboration among professionals and academics. Although it is not an open-access journal, the high impact factor underscores its value in the scholarly community, making it an essential resource for researchers, clinicians, and students dedicated to enhancing mental health practices and policies in the region and beyond.

Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.

PSYCHIATRIC QUARTERLY, published by Springer, stands as a pivotal resource in the field of psychiatry and mental health since its inception in 1927. With a reputable Q2 categorization in Psychiatry and Mental Health for 2023, this journal ranks impressively at #77 out of 567 in Scopus, placing it in the top 86th percentile of its category. Covering a diverse range of topics related to mental health, PSYCHIATRIC QUARTERLY aims to disseminate rigorous research findings, theoretical advancements, and clinical insights that contribute to improved mental health practices and policies. Although it does not offer open access, it provides substantial value to researchers, professionals, and students through its comprehensive analyses and scholarly articles. Located in New York, United States, the journal serves as an essential platform for advancing the understanding and treatment of psychiatric disorders, making it an invaluable addition to any academic library or research portfolio.